490 related articles for article (PubMed ID: 34087152)
41. COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.
Peter J
S Afr Med J; 2021 Feb; 111(4):291-294. PubMed ID: 33944757
[TBL] [Abstract][Full Text] [Related]
42. Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing?
Marcec R; Likic R
Br J Clin Pharmacol; 2021 Sep; 87(9):3632-3633. PubMed ID: 33580602
[No Abstract] [Full Text] [Related]
43. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
Gallagher ME; Sieben AJ; Nelson KN; Kraay ANM; Orenstein WA; Lopman B; Handel A; Koelle K
Nat Med; 2021 Jan; 27(1):4-5. PubMed ID: 33230343
[No Abstract] [Full Text] [Related]
44. Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent.
Minocha PK; Better D; Singh RK; Hoque T
J Pediatr; 2021 Nov; 238():321-323. PubMed ID: 34166671
[No Abstract] [Full Text] [Related]
45. Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination.
Hanneman K; Iwanochko RM; Thavendiranathan P
Radiology; 2021 Jun; 299(3):E282. PubMed ID: 33625301
[No Abstract] [Full Text] [Related]
46. Association of Facial Pustular Neutrophilic Eruption With Messenger RNA-1273 SARS-CoV-2 Vaccine.
Merrill ED; Kashem SW; Amerson EH; Pincus LB; Lang UE; Shinkai K; Chang AY
JAMA Dermatol; 2021 Sep; 157(9):1128-1130. PubMed ID: 34319363
[No Abstract] [Full Text] [Related]
47. The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines.
Bigini P; Gobbi M; Bonati M; Clavenna A; Zucchetti M; Garattini S; Pasut G
Nat Nanotechnol; 2021 Nov; 16(11):1169-1171. PubMed ID: 34732846
[No Abstract] [Full Text] [Related]
48. Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development.
Baay M; Neels P
Front Immunol; 2021; 12():658783. PubMed ID: 33777056
[No Abstract] [Full Text] [Related]
49. Covid-19 vaccination during Ramadan.
Mughal F
BMJ; 2021 Apr; 373():n862. PubMed ID: 33795237
[No Abstract] [Full Text] [Related]
50. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Sharma O; Sultan AA; Ding H; Triggle CR
Front Immunol; 2020; 11():585354. PubMed ID: 33163000
[TBL] [Abstract][Full Text] [Related]
51. In brief: Johnson & Johnson COVID-19 vaccine suspended.
Med Lett Drugs Ther; 2021 May; 63(1623):e1. PubMed ID: 33976102
[No Abstract] [Full Text] [Related]
52. 68Ga-DOTATOC-avid lymphadenopathies induced from COVID-19 mRNA vaccination.
Pudis M; Vercher Conejero JL; Martín Marcuartu JJ; Cortés Romera M
Jpn J Clin Oncol; 2021 Dec; 51(12):1765. PubMed ID: 34363083
[No Abstract] [Full Text] [Related]
53. Re: Unilateral axillary adenopathy in the setting of COVID-19 vaccine, Clinical Imaging, January 2021.
Finnegan J; Govender P; Torreggiani WC
Clin Imaging; 2021 Jul; 75():171-172. PubMed ID: 33838977
[No Abstract] [Full Text] [Related]
54. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).
Román GC; Gracia F; Torres A; Palacios A; Gracia K; Harris D
Front Immunol; 2021; 12():653786. PubMed ID: 33981305
[TBL] [Abstract][Full Text] [Related]
55. How to redesign COVID vaccines so they protect against variants.
Callaway E; Ledford H
Nature; 2021 Feb; 590(7844):15-16. PubMed ID: 33514888
[No Abstract] [Full Text] [Related]
56. Two cases of axillary lymphadenopathy diagnosed as diffuse large B-cell lymphoma developed shortly after BNT162b2 COVID-19 vaccination.
Mizutani M; Mitsui H; Amano T; Ogawa Y; Deguchi N; Shimada S; Miwa A; Kawamura T; Ogido Y
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e613-e615. PubMed ID: 35398921
[No Abstract] [Full Text] [Related]
57. Unilateral axillary adenopathy following COVID-19 vaccination: a multimodality pictorial illustration and review of current guidelines.
Brown A; Shah S; Dluzewski S; Musaddaq B; Wagner T; Szyszko T; Wan S; Groves A; Mokbel K; Malhotra A
Clin Radiol; 2021 Aug; 76(8):553-558. PubMed ID: 34053731
[TBL] [Abstract][Full Text] [Related]
58. Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine.
Julian JA; Mathern DR; Fernando D
Ann Emerg Med; 2021 Jun; 77(6):654-656. PubMed ID: 34030782
[No Abstract] [Full Text] [Related]
59. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.
Jedlowski PM; Jedlowski MF
Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560802
[No Abstract] [Full Text] [Related]
60. Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination.
Horvat JV; Sevilimedu V; Becker AS; Perez-Johnston R; Yeh R; Feigin KN
Eur Radiol; 2022 Aug; 32(8):5752-5758. PubMed ID: 35247087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
